Cullinan Therapeutics FY2025 net loss widens 31% to USD 219.88 million

Reuters03-10
<a href="https://laohu8.com/S/CGEM">Cullinan Therapeutics</a> FY2025 net loss widens 31% to USD 219.88 million

Cullinan reported a FY 2025 net loss attributable to shareholders of USD 219.88 million, compared with a FY 2024 net loss of USD 167.38 million. FY 2025 research and development expense rose 31% to USD 187.4 million, driven mainly by a one-time USD 20 million upfront in-licensing fee for velinotamig and higher clinical development and personnel costs. FY 2025 interest income fell 25% to USD 22.21 million. Cullinan ended FY 2025 with USD 377.9 million in cash, cash equivalents and short-term investments, plus USD 61.1 million in long-term investments and interest receivable, and said it expects existing capital resources to fund operations into 2029. In February 2026, partner Taiho completed a rolling NDA submission seeking accelerated approval for zipalertinib in previously treated EGFR exon 20 insertion NSCLC, and Cullinan said it is eligible for up to USD 130 million in U.S. regulatory milestone payments tied to the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-099362), on March 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment